Table 2.
Correlation analysis of serum NGF and BDNF levels with clinical parameters.
| Clinical parameters | Serum NGF level (pg/ml) | Serum BDNF level (pg/ml) | ||||
|---|---|---|---|---|---|---|
| >42.7 | ≤42.7 | p* | >1739.8 | ≤1739.8 | p# | |
| Gender (Male/Female) | 19/20 | 11/15 | 0.612 | 19/19 | 11/16 | 0.461 |
| Average age (years) | 57.7±8.0 | 8.8±6.2 | 0.383 | 58.7±7.1 | 57.3±7.6 | 0.279 |
| Height (cm) | 166.3±7.4 | 167.3±5.7 | 0.389 | 167.2±6.5 | 166.0±7.0 | 0.313 |
| Weight (kg) | 61.7±6.4 | 62.7±4.9 | 0.319 | 62.5±5.6 | 61.5±6.1 | 0.332 |
| Course of disease | 14.0±3.6 | 10.7±3.8 | <0.001 | 14.1±3.8 | 10.6±3.4 | <0.001 |
| FBG (mmol/L) | 9.1±1.5 | 9.3±1.2 | 0.403 | 9.3±1.4 | 9.1±1.5 | 0.433 |
| PGL (mmol/L) | 15.9±3.4 | 16.4±2.6 | 0.348 | 16.3±3.0 | 15.8±3.2 | 0.359 |
| FCP (ng/ml) | 6.6±1.2 | 4.7±1.1 | <0.001 | 6.7±1.1 | 4.7±1.1 | <0.001 |
| 2-h FCP (ng/ml) | 10.2±1.7 | 7.7±1.5 | <0.001 | 10.0±1.9 | 8.1±1.6 | <0.001 |
| HbAlc | 9.5±1.2 | 7.5±1.1 | <0.001 | 9.5±1.2 | 7.6±1.2 | <0.001 |
| TG (mmol/L) | 1.8±0.4 | 1.9±0.4 | 0.157 | 1.8±0.4 | 1.7±0.5 | 0.21 |
| Cholestenone (mmol/L) | 4.8±0.5 | 4.9±0.5 | 0.256 | 4.9±0.4 | 4.8±0.5 | 0.21 |
| HDL (mmol/L) | 1.3±0.4 | 1.4±0.4 | 0.157 | 1.4±0.4 | 1.3±0.4 | 0.157 |
| LDL (mmol/L) | 2.5±0.4 | 2.4±0.4 | 0.157 | 2.5±0.4 | 2.4±0.4 | 0.157 |
| 24 h UME (mg/d) | 127.5±13.2 | 110.8±8.9 | <0.001 | 126.4±15.5 | 113.1±7.4 | <0.001 |
NGF – nerve growth factor; BDNF – brain derived neurotrophic factor; FBG – fasting blood glucose; PGL – postprandial glucose level; FCP – fasting C-peptide; 2-h FCP – 2 h fasting C-peptide; HbAlc – glycosylated hemoglobin; TG – triglycerides; HDL – high-density lipoprotein; LDL – low-density lipoprotein; UME – urinary microalbumin excretion;
*
NGF ≤42.7 pg/ml vs. NGF ≤42.7pg/ml;
#
BDNF ≤1739.8 pg/ml vs. BDNF ≤1739.8.
The independent samples t-test was used to analyze data.